LOADING
Comparing NVIDIA Corporation (NVDA) and Eli Lilly and Company (LLY) across the Technology and Health Care sectors. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | NVDA | LLY |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $4.90T | $829.7B |
| P/E Ratio | 41.2 | 40.3 |
| Forward P/E | 24.8 | 27.3 |
| PEG Ratio | 0.72 | 1.00 |
| EPS | $4.90 | $22.99 |
| Revenue Growth (YoY) | 73.2% | 42.6% |
| Profit Margin | 55.6% | 31.7% |
| Return on Equity | 101.5% | 101.2% |
| Dividend Yield | 0.02% | 0.66% |
| Beta | 2.33 | 0.50 |
| 52-Week High | $212.17 | $1,132.06 |
| 52-Week Low | $95.02 | $620.46 |
| Volume | -- | -- |
NVIDIA Corporation is the larger company by market capitalization. Eli Lilly and Company trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Eli Lilly and Company offers a higher dividend yield for income investors. NVIDIA Corporation has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.